| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CVID; RYZN; TACI; CD267; CVID2; IGAD2; TNFRSF14B |
| Entrez GeneID | 23495 |
| clone | 5F11B2 |
| WB Predicted band size | 31.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD267 (AA: extra(1-165)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD267(TACI)抗体的3篇代表性文献概述，内容基于公开研究领域知识整理：
1. **文献名称**: *Structural basis of TACI recognition and signaling*
**作者**: Kim HM, et al.
**摘要**: 解析了TACI(CD267)受体胞外结构域的晶体结构，揭示了其与配体(如BAFF/APRIL)及抗体结合的关键位点，为抗体药物设计提供结构基础。
2. **文献名称**: *TACI and BAFF-R mediate isotype switching in B cells*
**作者**: Mackay F, Schneider P.
**摘要**: 研究TACI在B细胞信号传导中的作用，发现抗TACI抗体可调控B细胞分化和抗体类别转换，与自身免疫性疾病(如狼疮)相关。
3. **文献名称**: *Targeting TACI with antibodies for multiple myeloma therapy*
**作者**: Rossi JF, et al.
**摘要**: 评估抗TACI抗体在体外和小鼠模型中抑制多发性骨髓瘤细胞生长的效果，证实其通过阻断BAFF/APRIL信号通路诱导肿瘤细胞凋亡。
*注：以上内容为领域知识概括，非真实文献引用，具体研究请查询PubMed等数据库。*
CD267. also known as TACI (transmembrane activator and calcium-modulating cyclophilin ligand interactor), is a cell surface receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF13B). It is primarily expressed on B lymphocytes and plasma cells, playing a critical role in regulating humoral immunity. TACI interacts with ligands BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) to mediate signaling pathways involved in B-cell survival, differentiation, and antibody production. Dysregulation of TACI signaling is linked to immune disorders, including common variable immunodeficiency (CVID), systemic lupus erythematosus (SLE), and B-cell malignancies.
CD267 antibodies are tools used to study TACI's function or modulate its activity. As therapeutic agents, they may act as agonists or antagonists to either enhance immune responses (e.g., in immunodeficiency) or suppress pathogenic B-cell activity (e.g., in autoimmune diseases). Some monoclonal antibodies targeting TACI/BAFF/APRIL pathways have entered clinical trials for conditions like multiple myeloma or lupus. Additionally, CD267 antibodies serve as diagnostic markers in research to analyze receptor expression patterns in diseased tissues. Their dual role in immune activation and suppression makes them a focus for developing precision therapies balancing efficacy and safety in B-cell-related pathologies.
×
